2 total
Judicial review of the Patented Medicine Prices Review Board's decision is dismissed.
Galderma Canada Inc. sought judicial review of a decision by the Patented Medicine Prices Review Board ordering it to provide pricing information for Differin.
The Board had redetermined the matter following a Federal Court of Appeal decision.
The Federal Court dismissed the judicial review application, finding the Board's decision reasonable in concluding that the invention of Canadian Patent No. 2,478,237 pertained to the medicine Differin, given the significant clinical similarities.
Prolix statement of claim struck; claims of federal employees with grievance rights barred.
The Defendants brought a motion to strike a Statement of Claim filed by approximately 600 Plaintiffs challenging the federal government's COVID-19 vaccination policies.
The Court struck the Statement of Claim without leave to amend for those Plaintiffs employed within the Core Public Administration, finding their claims were barred by s. 236 of the Federal Public Sector Labour Relations Act as they had access to the grievance process.
For the remaining Plaintiffs, the Court struck the Statement of Claim with leave to amend, holding the pleading was prolix, lacked necessary material facts, and sought impermissible remedies.
